|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1995-5-18
|
|
pubmed:abstractText |
Macrophages activated by macrophage-colony stimulating factor (M-CSF) are potent immune effector cells and can mediate both in vitro cytotoxicity and antitumor effects in vivo. A Phase I trial combining M-CSF with R24, a mouse monoclonal antibody against GD3 ganglioside that has been shown to localize to melanoma tumors, induce inflammation at tumor sites, and result in major tumor responses in some patients with melanoma was performed.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD14,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol,
http://linkedlifedata.com/resource/pubmed/chemical/Gangliosides,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DR Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Macrophage Colony-Stimulating Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/ganglioside, GD3
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
75
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2251-7
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:7536122-Adult,
pubmed-meshheading:7536122-Aged,
pubmed-meshheading:7536122-Antibodies, Monoclonal,
pubmed-meshheading:7536122-Antigens, CD,
pubmed-meshheading:7536122-Antigens, CD14,
pubmed-meshheading:7536122-Antigens, Differentiation, Myelomonocytic,
pubmed-meshheading:7536122-Breast Neoplasms,
pubmed-meshheading:7536122-Cholesterol,
pubmed-meshheading:7536122-Female,
pubmed-meshheading:7536122-Gangliosides,
pubmed-meshheading:7536122-Gene Expression,
pubmed-meshheading:7536122-HLA-DR Antigens,
pubmed-meshheading:7536122-Humans,
pubmed-meshheading:7536122-Infusions, Intravenous,
pubmed-meshheading:7536122-Liver Neoplasms,
pubmed-meshheading:7536122-Lymphatic Metastasis,
pubmed-meshheading:7536122-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:7536122-Male,
pubmed-meshheading:7536122-Melanoma,
pubmed-meshheading:7536122-Middle Aged,
pubmed-meshheading:7536122-Monocytes,
pubmed-meshheading:7536122-Pruritus,
pubmed-meshheading:7536122-Recombinant Proteins,
pubmed-meshheading:7536122-Survival Rate,
pubmed-meshheading:7536122-Thrombocytopenia,
pubmed-meshheading:7536122-Urticaria
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma.
|
|
pubmed:affiliation |
Department of Medicine and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase I
|
